Hirofumi Yoshino

10PUBLICATIONS
11CO-AUTHORS
Molecular targetsMechanobiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Forensic epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 28, 2026
MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening.

|Dec 21, 2025
Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.

Gang Li, Shuichi Tatarano, Hirofumi Yoshino

|Aug 06, 2025
Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.

Junya Arima, Hirofumi Yoshino, Shuichi Tatarano

|Feb 26, 2025
Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Saeki Saito, Hirofumi Yoshino, Seiya Yokoyama

|Jun 19, 2024
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.

Junya Arima, Hirofumi Yoshino, Wataru Fukumoto

|Jun 14, 2024
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.

Ichiro Kawahara, Hirofumi Yoshino, Wataru Fukumoto

Pageof 2

Frequent Collaborators

5 joint publications

Hideki Enokida

3 joint publications

Shuichi Tatarano

3 joint publications

Junya Arima

1 joint publications

Masaya Yonemori